| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2d85d5fd4d4dd7f6d378869ab42f90a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ee11b1ea0b6f21b358b1496a098501b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e31c9bf060030dd1d746db4b707245d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd202a425419b9b183190425474b5bd9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2008-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5fed09b992fadff529fe2d0714826e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b15709d93805944e0b72396f288b4661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59cc2923f4b42dbd99d3db91413d02d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2af315042fb05fa5e23b4f8fe920dd2 |
| publicationDate |
2009-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009286729-A1 |
| titleOfInvention |
Epidermal Growth Factor Receptor Antagonists and Methods of Use |
| abstract |
The present invention features epidermal growth factor receptor (EGFR) antagonists. These EGFR antagonists are polypeptide variants of ligands of EGFR. The EGFR ligand polypeptide variants of the invention possess EGFR antagonistic properties and can inhibit at least one EGFR-mediated biological activity such as inhibition of the receptor's kinase activation activity and subsequently, cell proliferation. Such polypeptide variants, and nucleic acids encoding these polypeptide variants can be used therapeutically in situations in which inhibition of EGFR activity is indicated. |
| priorityDate |
2004-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |